Lianhuaqingwen Exerts Anti-Viral and Anti-Inflammatory Activity Against Novel Coronavirus (SARS-CoV-2)
Auteurs : Li Runfeng, Hou Yunlong, Huang Jicheng, Pan Weiqi , Ma Qinhai, Shi Yongxia , Li Chufang, Zhao Jin, Jia Zhenhua, Jiang Haiming, Zheng Kui, Huang Shuxiang, Dai Jun, Li Xiaobo, Hou Xiaotao, Wang Lin, Zhong Nanshan, Yang Zifeng.
Production : Pharmacological Research, Volume 156, June 2020, 104761
Diffusion : ScienceDirect, site web géré par l’éditeur Elsevier.
Date : Reçu le 29 février 2020, révisé le 14 mars 2020, accepté le 17 mars 2020, disponible en ligne le 20 mars 2020.
Purpose: Lianhuaqingwen (LH) as traditional Chinese medicine (TCM) formula has been used to treat influenza and exerted broad-spectrum antiviral effects on a series of influenza viruses and immune regulatory effects Ding et al. (2017). The goal of this study is to demonstrate the antiviral activity of LH against the novel SARS-CoV-2 virus and its potential effect in regulating host immune response.
Source : Li Runfeng, Hou Yunlong, Huang Jicheng et al., “Lianhuaqingwen Exerts Anti-Viral and Anti-Inflammatory Activity Against Novel Coronavirus (SARS-CoV-2)”, Pharmacological Research, Volume 156, June 2020, 104761. DOI : https://doi.org/10.1016/j.phrs.2020.104761 (consulté le 22/05/2020).
Photo “à la une” : Fig. 3. Virions in the ultra sections of infected Vero E6 cells under electron microscope. (A, F) uninfected cells, (B, G) mock-treated SARS-CoV-2 virus infected cells, (C, D, H, I) infected cells with LH treatment, (E, J) infected cells with remdesivir treatment. White arrows indicated the spindle sharp of viral particles in infected cells with LH treatment. © Pharmacological Research / Elsevier